Webinars on demand

In 2012, cancer was the second leading cause of mortality in the world with 8.2 million cancer-related deaths.

During this webinar, Dr. Cornish will present the unique perspectives of a practicing pathologist on the emerging field of Computational Pathology and Artificial Intelligence.

Impact on KRAS/NRAS/EGFR Mutation Analysis and Personalized Cancer Treatment

The merging of three North Wales hospital pathology departments formed one of the largest labs in the country, serving a population of 700,000.

Is there a need for computational pathology in hospitals today? Are current hospital technologies ready for the change?

Tumour-specific mutations in plasma can serve as biomarkers for tumour detection, monitoring tumour response to therapies, detecting residual disease, and enabling long-term follow-up.

What can you expect from a successful protocol?

Assessment of molecular heterogeneity in tumor is a challenging task. For the first time, Palanisamy et al. have demonstrated the existence of a rare subset of prostate cancer with heterogeneous molecular aberrations involving ETS family genes and SPINK1 expression utilizing both standard immunohistochemistry (IHC) and RNA in situ hybridization (Advanced Cell Diagnostics RNAscope® Technology).

Over the last 10 years Liquid Chromatography Mass Spectrometry (LC/MS/MS) has been adopted by many clinical laboratories and been successfully implemented as the technology has become more robust, reliable and affordable

Next-generation sequencing (NGS) is a cornerstone of precision oncology, providing critical insights for the accurate diagnosis and tailored treatment of various cancers.